S&P 500   3,295.94 (+0.04%)
DOW   26,757.95 (+0.35%)
QQQ   268.88 (-0.19%)
AAPL   439.37 (+0.83%)
MSFT   211.89 (-2.15%)
FB   249.19 (-1.10%)
GOOGL   1,466.38 (-1.10%)
AMZN   3,112.75 (+0.03%)
NVDA   444.16 (+0.85%)
CGC   18.96 (-0.52%)
BABA   261.00 (+1.19%)
TSLA   1,469.78 (-1.02%)
MU   50.84 (+0.89%)
GE   6.14 (+0.49%)
AMD   84.91 (+9.32%)
T   30.06 (+1.49%)
F   6.74 (+0.75%)
ACB   10.46 (+0.38%)
GILD   70.65 (-1.51%)
NFLX   505.10 (+1.30%)
DIS   117.88 (+1.31%)
BAC   24.95 (-0.16%)
BA   164.23 (+1.21%)
S&P 500   3,295.94 (+0.04%)
DOW   26,757.95 (+0.35%)
QQQ   268.88 (-0.19%)
AAPL   439.37 (+0.83%)
MSFT   211.89 (-2.15%)
FB   249.19 (-1.10%)
GOOGL   1,466.38 (-1.10%)
AMZN   3,112.75 (+0.03%)
NVDA   444.16 (+0.85%)
CGC   18.96 (-0.52%)
BABA   261.00 (+1.19%)
TSLA   1,469.78 (-1.02%)
MU   50.84 (+0.89%)
GE   6.14 (+0.49%)
AMD   84.91 (+9.32%)
T   30.06 (+1.49%)
F   6.74 (+0.75%)
ACB   10.46 (+0.38%)
GILD   70.65 (-1.51%)
NFLX   505.10 (+1.30%)
DIS   117.88 (+1.31%)
BAC   24.95 (-0.16%)
BA   164.23 (+1.21%)
S&P 500   3,295.94 (+0.04%)
DOW   26,757.95 (+0.35%)
QQQ   268.88 (-0.19%)
AAPL   439.37 (+0.83%)
MSFT   211.89 (-2.15%)
FB   249.19 (-1.10%)
GOOGL   1,466.38 (-1.10%)
AMZN   3,112.75 (+0.03%)
NVDA   444.16 (+0.85%)
CGC   18.96 (-0.52%)
BABA   261.00 (+1.19%)
TSLA   1,469.78 (-1.02%)
MU   50.84 (+0.89%)
GE   6.14 (+0.49%)
AMD   84.91 (+9.32%)
T   30.06 (+1.49%)
F   6.74 (+0.75%)
ACB   10.46 (+0.38%)
GILD   70.65 (-1.51%)
NFLX   505.10 (+1.30%)
DIS   117.88 (+1.31%)
BAC   24.95 (-0.16%)
BA   164.23 (+1.21%)
S&P 500   3,295.94 (+0.04%)
DOW   26,757.95 (+0.35%)
QQQ   268.88 (-0.19%)
AAPL   439.37 (+0.83%)
MSFT   211.89 (-2.15%)
FB   249.19 (-1.10%)
GOOGL   1,466.38 (-1.10%)
AMZN   3,112.75 (+0.03%)
NVDA   444.16 (+0.85%)
CGC   18.96 (-0.52%)
BABA   261.00 (+1.19%)
TSLA   1,469.78 (-1.02%)
MU   50.84 (+0.89%)
GE   6.14 (+0.49%)
AMD   84.91 (+9.32%)
T   30.06 (+1.49%)
F   6.74 (+0.75%)
ACB   10.46 (+0.38%)
GILD   70.65 (-1.51%)
NFLX   505.10 (+1.30%)
DIS   117.88 (+1.31%)
BAC   24.95 (-0.16%)
BA   164.23 (+1.21%)
Log in

ETR:MRKMerck KGaA Stock Price, Forecast & News

€112.30
+4.25 (+3.93 %)
(As of 07/14/2020)
Add
Compare
Today's Range
€108.15
Now: €112.30▼
€112.55
50-Day Range
€99.62
MA: €107.89▼
€115.95
52-Week Range
€76.22
Now: €112.30▼
€125.95
Volume387,020 shs
Average VolumeN/A
Market Capitalization$14.51 billion
P/E Ratio30.68
Dividend Yield2.33%
BetaN/A
MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. It offers prescription medicines to treat cancer, multiple sclerosis, infertility, growth deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, as well as squamous cell carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments. The company also provides life science products and services for use in the discovery, development, and manufacture of drug therapies, as well as in laboratories; and specialty chemicals for use in displays, computer chips, surfaces, Integrated circuits, microelectronic systems, anti-reflection coatings, and cosmetics. It has alliances with Pfizer Inc., Bristol-Myers Squibb Company, Intrexon Corporation, Avillion LLP., F-star Delta Ltd, SFJ Pharmaceuticals Group, Alibaba Health, Checkmate Pharmaceuticals, Solvias, and Leap Therapeutics, Inc., as well as a collaboration with Daiichi Sankyo Company, Limited. The company was founded in 1668 and is headquartered in Darmstadt, Germany. MERCK Kommanditgesellschaft auf Aktien is a subsidiary of E. Merck Kommanditgesellschaft.
Read More

Beat the Market (BTM) Rank™

Analyst Opinion: 0.0Community Rank: 2.9Dividend Strength: 1.7Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

0.91 out of 5 stars


Industry, Sector and Symbol

Stock Exchange ETR
Industry Drug Manufacturers - Specialty & Generic
Sub-IndustryN/A
SectorMedical
Current SymbolETR:MRK
Previous Symbol
CUSIPN/A
CIKN/A
Webwww.merckgroup.com
Phone49 6151 72 0

Debt

Debt-to-Equity Ratio74.48
Current Ratio0.93
Quick Ratio0.56

Price-To-Earnings

Trailing P/E Ratio30.68
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$16.78 billion
Price / Sales0.87
Cash Flow€3.66 per share
Price / Cash Flow30.67
Book Value€42.73 per share
Price / Book2.63

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Employees51,039
Outstanding Shares129,242,000
Market Cap$14.51 billion
Next Earnings Date8/6/2020 (Estimated)
OptionableOptionable
€112.30
+4.25 (+3.93 %)
(As of 07/14/2020)
30 days | 90 days | 365 days | Advanced Chart

Receive MRK News and Ratings via Email

Sign-up to receive the latest news and ratings for MRK and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Merck KGaA (ETR:MRK) Frequently Asked Questions

How has Merck KGaA's stock been impacted by COVID-19 (Coronavirus)?

Merck KGaA's stock was trading at €98.68 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, MRK shares have increased by 13.8% and is now trading at €112.30.
View which stocks have been most impacted by Coronavirus.

When is Merck KGaA's next earnings date?

Merck KGaA is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020.
View our earnings forecast for Merck KGaA.

Has Merck KGaA been receiving favorable news coverage?

Media stories about MRK stock have been trending somewhat negative recently, InfoTrie Sentiment reports. InfoTrie scores the sentiment of press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Merck KGaA earned a news sentiment score of -1.7 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the stock's share price in the next several days.
View the latest news about Merck KGaA.

Who are some of Merck KGaA's key competitors?

Some companies that are related to Merck KGaA include Canopy Growth (WEED), Bausch Health Companies (BHC), Hikma Pharmaceuticals (HIK), Evotec (EVT), Aphria (APHA), Aurora Cannabis (ACB), Knight Therapeutics (GUD), Ecofibre (EOF), HLS Therapeutics (HLS), Hexo (HEXO), HEXO (HEXO), OrganiGram (OGI), Next Science (NXS), Amryt Pharma (AMYT) and Benchmark (BMK).
View all competitors.

What other stocks do shareholders of Merck KGaA own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Merck KGaA investors own include Berkshire Hathaway (BRK.B), Walt Disney (DIS), Eli Lilly And Co (LLY), Medtronic (MDT), AbbVie (ABBV), Abbott Laboratories (ABT), Adobe (ADBE), Aldeyra Therapeutics (ALDX), Ares Capital (ARCC) and Boeing (BA).

Who are Merck KGaA's key executives?

Merck KGaA's management team includes the following people:
  • Dr. Stefan Oschmann, Chairman of Exec. Board & CEO (Age 62)
  • Dr. Marcus Kuhnert, CFO & Member of Exec. Board (Age 51)
  • Dr. Kai Beckmann, CEO of Performance Materials & Member of the Exec. Board (Age 54)
  • Dr. Udit Batra, CEO of Life Science & Member of Exec. Board (Age 48)
  • Ms. Belén Garijo López M.D., CEO of Healthcare & Member of the Exec. Board (Age 59)

What is Merck KGaA's stock symbol?

Merck KGaA trades on the ETR under the ticker symbol "MRK."

What is Merck KGaA's stock price today?

One share of MRK stock can currently be purchased for approximately €112.30.

How big of a company is Merck KGaA?

Merck KGaA has a market capitalization of $14.51 billion and generates $16.78 billion in revenue each year. Merck KGaA employs 51,039 workers across the globe.

What is Merck KGaA's official website?

The official website for Merck KGaA is www.merckgroup.com.

How can I contact Merck KGaA?

The company can be reached via phone at 49 6151 72 0.

This page was last updated on 8/4/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.